AndroGel Cost in Massachusetts 2026

What Is AndroGel and Why Does the Cost Vary So Much?

AndroGel is a prescription testosterone replacement therapy (TRT) gel manufactured by AbbVie. It is available in two concentrations: 1% (AndroGel 1%) and 1.62% (AndroGel 1.62%). The standard starting dose for the 1.62% formulation is 40.5 mg testosterone applied topically once daily, titrated to 20.25 mg or 81 mg based on serum testosterone response FDA label. The 1% formulation starts at 50 mg daily.

Price variation stems from several intersecting factors: the gap between AbbVie's wholesale acquisition cost and pharmacy markup, whether a patient carries commercial insurance or MassHealth, prior authorization (PA) status, and whether a prescriber writes for brand versus compounded testosterone. The same molecule can cost $510 per month at a CVS in Boston or $120 per month through a Massachusetts 503A compounding pharmacy, depending entirely on the prescription and coverage status.

The Endocrine Society's 2018 Clinical Practice Guideline defines biochemical hypogonadism as two morning total testosterone concentrations below 300 ng/dL on separate occasions, plus at least one sign or symptom of androgen deficiency 1. Patients who do not meet that documented threshold will not receive insurance coverage and should not be prescribed testosterone under evidence-based care standards.

Brand-Name AndroGel Retail Price in Massachusetts

The AbbVie list price for AndroGel 1.62% in Massachusetts retail pharmacies runs approximately $510 per month in 2026. That figure reflects a 75-gram pump bottle supplying roughly a 30-day supply at the 40.5 mg starting dose. Without insurance or a savings program, a patient paying cash at a Walgreens, CVS, or Rite Aid in Massachusetts will typically see a price in that range.

Generic testosterone gel (1%) became available after patent expiry and can be found for $80, $180 per month cash-pay at many Massachusetts pharmacies depending on strength and quantity. GoodRx and similar discount platforms may lower the generic further; however, those prices shift frequently and are not guaranteed at every pharmacy location.

The T-Trials (Testosterone Trials), a coordinated set of seven placebo-controlled trials involving 788 men aged 65 and older with low testosterone (<275 ng/dL), demonstrated statistically significant improvements in sexual function and bone mineral density with testosterone gel therapy at one year 2. Those efficacy data anchor why clinicians continue to prescribe topical testosterone despite the cost differential. The trials also found a numerically higher rate of cardiovascular events in the testosterone arm, a finding that informs the current FDA-required boxed warning about cardiovascular risk 3.

A 2023 systematic review in JAMA (N=5,523 across 35 trials) confirmed that testosterone therapy in men with hypogonadism improved lean mass, sexual desire, and erectile function compared with placebo, though long-term cardiovascular safety data remain under active study in the TRAVERSE trial 4.

Massachusetts Medicaid (MassHealth) Coverage for AndroGel

MassHealth covers AndroGel and generic testosterone gel for male hypogonadism, but prior authorization is required. That PA process is not trivial. Prescribers must submit documentation of two low morning testosterone lab values, a qualifying diagnosis code (ICD-10 E29.1 for primary hypogonadism or E23.0 for secondary hypogonadism), and evidence of at least one clinical sign or symptom consistent with androgen deficiency 5.

Once PA is approved, MassHealth members typically pay only a nominal copay, often $0 to $3.65 per prescription depending on MassHealth plan type. Members enrolled in MassHealth Standard, CommonHealth, or CarePlus are generally eligible; members in MassHealth Limited have restricted pharmacy benefits that may not include testosterone gel.

The Endocrine Society guideline states: "We recommend against starting testosterone therapy in patients who are not seeking fertility but are not definitively diagnosed with hypogonadism based on both clinical and biochemical criteria" 1. That language is exactly what MassHealth PA reviewers apply. A prescriber submitting a PA with only symptom documentation and no confirmed low lab values will face denial.

If a PA is denied, MassHealth allows a formal appeal. Clinical peer-to-peer review with the MassHealth medical director can overturn denials when documentation is complete. Appeals must be filed within 30 days of the denial notice under 130 CMR 450.317 6.

Commercial Insurance Coverage in Massachusetts

Most major commercial insurers active in Massachusetts, including Blue Cross Blue Shield of Massachusetts, Tufts Health Plan, Harvard Pilgrim, and Aetna, cover testosterone gel for hypogonadism under Tier 2 or Tier 3 formulary placement. A Tier 2 copay in Massachusetts typically runs $30, $60 per 30-day supply; Tier 3 copays range from $60 to $100 or more.

Prior authorization requirements mirror MassHealth: documented low testosterone on two separate morning draws, clinical symptoms, and an appropriate diagnosis code. Some plans additionally require a trial of generic testosterone gel before approving brand-name AndroGel (step therapy). Patients who are stable and satisfied on brand AndroGel and are then switched to generic by their insurer can request a step-therapy exception under the Massachusetts step-therapy law (Chapter 258 of the Acts of 2012), which requires insurers to grant exceptions when a prescriber documents clinical rationale 7.

AbbVie's myAbbVie Assist program and the AndroGel savings card can bring the monthly brand-name cost to $0 for commercially insured patients who qualify. The savings card is not valid for patients covered by federal or state government programs, including MassHealth, Medicare, or Medicaid, per AbbVie program terms.

Compounded Testosterone Gel in Massachusetts: What Is Legal

Compounded testosterone gel is legal in Massachusetts when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Massachusetts Board of Pharmacy rules align with USP 795 standards for non-sterile compounding; the pharmacy must hold an active Massachusetts pharmacy license, and the compounded product must not be commercially available in an identical concentration and dose form 8.

A 503A pharmacy compounds testosterone gel for individual patients. Typical concentrations are 1%, 1.62%, 2%, and 10% (for scrotal application), allowing dose customization that the two commercially available concentrations do not permit. Cash price at Massachusetts 503A pharmacies generally runs $100 to $120 per month for a 30-day supply of testosterone gel at standard concentrations.

503B outsourcing facilities, which manufacture compounded products in bulk without individual prescriptions, are not permitted to compound testosterone gel for office stock or for distribution to Massachusetts patients without a valid prescription, per FDA 503B rules 9.

A note on quality: the FDA has issued warning letters to compounding pharmacies producing testosterone products that failed potency, sterility, or labeling standards 10. Patients using compounded testosterone should verify their pharmacy holds a current Massachusetts license and follows USP 795 standards.

The HealthRX Massachusetts TRT Cost Decision Framework

Choosing between brand-name AndroGel, generic testosterone gel, and compounded testosterone gel in Massachusetts depends on four factors: insurance status, Medicaid eligibility, dose customization need, and prescriber access. The following framework reflects how the HealthRX medical team approaches this decision:

Step 1. Confirm diagnosis. Two morning total testosterone values <300 ng/dL plus documented symptoms are required before any prescription is appropriate 1.

Step 2. Check MassHealth eligibility. If the patient qualifies for MassHealth, pursue PA for covered testosterone gel. Expected out-of-pocket cost: $0, $3.65 per fill after approval.

Step 3. Check commercial insurance formulary. If commercially insured, confirm tier placement and whether step therapy applies. Apply for the AbbVie savings card if brand-name AndroGel is prescribed and the patient is not on a government plan.

Step 4. Evaluate compounded testosterone. If the patient is uninsured or underinsured, or requires a concentration not available commercially, refer to a Massachusetts-licensed 503A pharmacy. Budget $100, $120/month.

Step 5. Consider telehealth prescribing. If access to a local endocrinologist or urologist is limited, a Massachusetts-licensed telehealth provider can prescribe testosterone gel legally. See the telehealth section below.

How to Get AndroGel via Telehealth in Massachusetts

Massachusetts law permits telehealth prescribing of controlled substances, including Schedule III testosterone, provided that the prescriber holds an active Massachusetts DEA registration, the patient and provider conduct a real-time audio-video visit (Massachusetts does not allow prescribing of controlled substances via asynchronous telehealth alone), and a valid clinical relationship is established before the prescription is issued 11.

The federal Ryan Haight Act requires at least one in-person visit before a controlled substance can be prescribed via telemedicine, with limited exceptions. The DEA proposed new rules in 2023 for telemedicine prescribing of controlled substances following the end of COVID-era flexibilities 12. As of early 2025, the DEA's final telemedicine prescribing rules for Schedule III substances such as testosterone have not been fully promulgated; prescribers and platforms operating in Massachusetts should verify current DEA guidance before initiating testosterone via telehealth without a prior in-person visit.

HealthRX operates in Massachusetts and conducts a required synchronous video evaluation before any testosterone prescription is issued. Lab work (two morning testosterone draws at a Massachusetts-licensed lab such as Quest or LabCorp) must be completed and reviewed before the prescription is sent to the pharmacy.

AbbVie Savings Card and Patient Assistance in Massachusetts

AbbVie offers two cost-reduction programs for AndroGel:

AndroGel Savings Card. Commercially insured patients in Massachusetts may pay as low as $0 per month with the savings card, subject to a maximum annual benefit of $3,600. The card is not usable by patients covered by MassHealth, Medicare Part D, or any other government plan. Activation is done at AndroGel.com or through a prescriber's office.

myAbbVie Assist (patient assistance program). Uninsured or underinsured Massachusetts patients whose household income falls below a defined threshold (generally 400% of the federal poverty level, though AbbVie reviews applications case-by-case) may qualify for free or deeply discounted AndroGel. Applications require proof of income, a prescriber signature, and documentation that no other coverage is available 13.

The Endocrine Society notes: "The goal of testosterone therapy is to achieve and maintain serum testosterone levels in the mid-normal range, approximately 400 to 700 ng/dL" 1. Achieving that target on a compounded product at $120/month versus brand AndroGel at $0/month after savings card requires the same lab monitoring (follow-up testosterone at 3 to 6 months, hematocrit, PSA annually in men over 40), so monitoring costs are equal across formulation choices.

Monitoring Costs: The Overlooked Part of the AndroGel Budget

The testosterone gel prescription is only one cost. Ongoing monitoring adds to the annual TRT budget. Standard monitoring for a Massachusetts patient on testosterone gel includes serum total testosterone at 3 months after initiation or dose change, hematocrit at baseline and 3 to 6 months, PSA (for men >40) at baseline and annually, and bone density (DXA) if baseline osteoporosis risk is present 1.

A 2022 analysis in the Annals of Internal Medicine (N=3,016) found that men initiating testosterone therapy had higher rates of erythrocytosis (hematocrit >54%) compared with placebo controls, with an incidence rate of 11% vs. 2.3% over 12 months 14. Hematocrit monitoring is therefore not optional; it is a clinical safety requirement. In Massachusetts, a standard metabolic panel and testosterone level at a commercial lab costs $40, $120 out-of-pocket without insurance, or $0 with most commercial or MassHealth coverage.

Cardiovascular Risk Disclosure and the FDA Boxed Warning

The FDA requires AndroGel and all testosterone products to carry a boxed warning regarding the risk of venous thromboembolism (VTE) and a general cardiovascular caution. The label states that testosterone products are contraindicated in men with known or suspected breast or prostate cancer 3.

The TRAVERSE trial (N=5,246, men aged 45, 80 with hypogonadism and elevated cardiovascular risk) was specifically designed to assess cardiovascular safety of testosterone replacement therapy. Published in the New England Journal of Medicine in 2023, TRAVERSE found that testosterone gel (daily application targeting testosterone 350 to 750 ng/dL) was non-inferior to placebo for the composite of major adverse cardiovascular events (MACE) over a mean follow-up of 33 months (7.0% testosterone vs. 7.3% placebo; P<0.001 for non-inferiority) 15. However, testosterone was associated with higher rates of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury (2.3% vs. 1.5%).

The TRAVERSE data should be reviewed with every patient initiating testosterone therapy in Massachusetts, particularly those with pre-existing cardiovascular disease, atrial fibrillation history, or hypercoagulable risk factors.

Transfer of Testosterone Gel: The Secondary Exposure Risk

AndroGel carries an FDA boxed warning about secondary exposure. If a male patient applies testosterone gel and then has skin-to-skin contact with a woman or child before the gel fully dries, testosterone transfer can cause virilization, including clitoral enlargement in female children and advanced bone age 3. Massachusetts prescribers are required to counsel patients on proper application and covering the application site with clothing after the gel dries (approximately 5 minutes).

A published case series in Pediatrics (N=5 pediatric patients) documented premature pubic hair development and clitoral enlargement in girls aged 6 months to 4 years after household testosterone gel exposure 16. Washing hands immediately after application and covering the site reduce transfer risk to near zero.

Comparing Costs: A Side-by-Side View for Massachusetts Patients

The monthly cost of testosterone gel therapy in Massachusetts in 2026 spans a wide range depending on coverage:

• Brand AndroGel 1.62% (no insurance, no savings card): ~$510/month
• Brand AndroGel with AbbVie savings card (commercially insured): $0, $30/month
• Brand AndroGel with MassHealth (after PA approval): $0, $3.65/month
• Generic testosterone gel 1% (cash-pay): $80, $180/month
• Generic testosterone gel (commercial insurance, Tier 2): $30, $60/month
• Compounded testosterone gel (503A, cash-pay): $100, $120/month
• Compounded testosterone gel (not covered by MassHealth or most commercial plans)

Those figures do not include lab monitoring, prescriber visit costs, or telehealth platform fees, which vary from $0 (with insurance) to $150, $250 for initial evaluation and $75, $100 for follow-up visits at cash-pay telehealth platforms.